MMIT’s Annual State of the Industry Survey
In an attempt to shed light on the current and future patient access landscape, we conduct a comprehensive industry survey alongside our sister company, The Dedham Group. Our goal is to better understand how pharma leaders today are planning for potential access problems tomorrow.
By sharing these insights and our key perspectives on what it all means, our hope is to equip companies with the information they need to power their commercial decision-making—and ensure the right patient gets access to the right treatment at the right time.
Below, you’ll find previous years’ resources from our annual industry research.
Ready to Learn More?
2024
INFOGRAPHIC
Overcome Unique Access Barriers
Here's a look at the six therapeutic areas that are generating the most excitement from industry leaders, and the anticipated hurdles to access.
REPORT
The 2024 State of Patient Access
Learn the key findings from our survey along with in-depth analysis of what pharma companies need to know to improve their access strategies.
ARTICLE
Understanding Access Barriers in 2024 and Beyond
In this blog, you’ll get the highlights from our survey along with the five key patient access issues that are top of mind for pharma and biotech execs, from increasing payer restrictions to regulatory concerns to exciting yet unknown emerging technologies.
INFOGRAPHIC
Reliance on Real-World Data Across the Product Lifecycle
Our findings show that 72% of pharma companies use real-world data to diagnose market access issues and prioritize interventions.
WEBINAR
Overcoming the Barriers to Patient Access
In this BioPharma Dive webinar, experts from MMIT and The Dedham Group share the results of the 2024 State of Patient Access Survey and explain how companies are navigating these complex access challenges.